Polycythemia Pipeline Summary

DelveInsight’s, “Polycythemia - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Polycythemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Polycythemia: Understanding

Polycythemia: Overview

Polycythemia, also known as erythrocytosis, refers to an abnormal increase in absolute red blood cell mass, typically reflected by elevated hemoglobin or hematocrit levels relative to age- and sex-specific reference ranges. Although red cell mass was historically measured directly, current clinical practice primarily relies on hemoglobin and hematocrit values, which can vary according to factors such as altitude, ethnicity, and geographic region. Polycythemia vera (PV) is a specific subtype of polycythemia and is an acquired, Philadelphia chromosome–negative myeloproliferative neoplasm characterized predominantly by excessive red blood cell production, often accompanied by increased white blood cells and platelets. The clinical manifestations of erythrocytosis are primarily associated with increased blood viscosity and the resulting risk of thrombosis, although bleeding complications may also occur. In PV, disease management also considers the potential for leukemic transformation, particularly following prolonged exposure to cytotoxic therapies.

Polycythemia is broadly classified into spurious (relative) and true (absolute) polycythemia. Spurious polycythemia results from reduced plasma volume rather than a genuine increase in red blood cell mass and may occur with severe fluid loss, such as from vomiting or diarrhea, or in Gaisböck syndrome, which is associated with factors such as hypertension, smoking, obesity, and diuretic use. True polycythemia is further classified according to serum erythropoietin (EPO) levels. Primary polycythemia, characterized by low EPO levels, includes polycythemia vera and primary familial or congenital polycythemia. In contrast, secondary polycythemia is associated with elevated EPO levels and may result from chronic hypoxia due to high altitude, respiratory or cyanotic heart diseases, renal disorders, smoking-related carboxyhemoglobinemia, high-affinity hemoglobin variants, EPO-secreting tumors, or medications such as erythropoietin analogs, anabolic steroids, and testosterone. Neonatal polycythemia is distinct from adult forms, as newborns normally have relatively higher hematocrit levels due to physiological adaptation to lower oxygen availability during fetal development, which is further influenced by the higher oxygen affinity of fetal hemoglobin.

The pathophysiology of polycythemia varies according to its underlying cause. In secondary polycythemia with elevated erythropoietin (EPO), cellular hypoxia stimulates EPO production primarily by renal peritubular interstitial cells, with a smaller contribution from the liver. EPO subsequently acts on erythroid progenitor cells to promote red blood cell production. In polycythemia vera with low EPO levels, the disease is driven primarily by acquired mutations in the JAK2 gene, most commonly involving the V617F variant, with some cases involving exon 12 mutations. These alterations disrupt normal inhibitory regulation of JAK2, resulting in constitutive signaling, increased sensitivity to EPO, and EPO-independent erythroid cell proliferation, ultimately leading to excessive red blood cell production.

Because polycythemia has diverse potential causes, its evaluation should be systematic and guided by the clinical context. Initial assessment typically includes a complete blood count, which may show elevated hemoglobin and hematocrit along with increased platelet and leukocyte counts in polycythemia vera. Red cell mass studies using radiolabeled autologous RBCs can distinguish true from spurious polycythemia but are rarely used in current practice. Serum erythropoietin (EPO) levels help guide further evaluation: low EPO suggests primary polycythemia and warrants JAK2 mutation testing for polycythemia vera, whereas elevated EPO points toward secondary polycythemia and prompts investigation for underlying hypoxia or other causes. Assessment may include oxygen saturation, carboxyhemoglobin levels, P50 testing for high-affinity hemoglobin variants, and evaluation for EPO-producing tumors. Additional laboratory investigations, including serum ferritin, vitamin B12, folate, renal function, uric acid, and hepatic function, can provide supportive diagnostic information and help identify secondary causes. Abdominal ultrasonography with Doppler, along with targeted investigations such as chest imaging, pulmonary function testing, sleep studies, or echocardiography, may be performed when an underlying cardiopulmonary, renal, or hepatic cause is suspected.

Treatment of secondary polycythemia primarily focuses on addressing the underlying cause. Phlebotomy remains the cornerstone of treatment for polycythemia vera and is also considered in selected cases of secondary polycythemia, particularly when hyperviscosity or thrombotic risk is significant. Hydroxyurea is generally used as a second-line cytoreductive therapy in polycythemia vera, particularly when phlebotomy is inadequate or poorly tolerated, while ruxolitinib, a JAK2 inhibitor, is an option for patients who are intolerant or resistant to hydroxyurea, although its use may be limited by adverse effects such as anemia and thrombocytopenia. Low-dose aspirin is commonly used to reduce thrombotic risk when not contraindicated. Additional management is directed toward complications and associated conditions, including allopurinol or febuxostat for significant hyperuricemia and antihistamines or selective serotonin reuptake inhibitors for pruritus. During pregnancy, phlebotomy and low-dose aspirin are generally used, with pegylated interferon-? considered for higher-risk patients. Neonatal polycythemia is usually managed conservatively, with exchange transfusion reserved for selected cases of significant hyperviscosity.

"Polycythemia- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycythemia pipeline landscape is provided which includes the disease overview and Polycythemia treatment guidelines. The assessment part of the report embraces, in depth Polycythemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycythemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Polycythemia R&D. The therapies under development are focused on novel approaches to treat/improve Polycythemia.

Polycythemia Emerging Drugs Chapters

This segment of the Polycythemia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polycythemia Emerging Drugs

Bomedemstat: Merck Sharp & Dohme

Bomedemstat (MK-3543) is an investigational small-molecule, irreversible inhibitor of lysine-specific demethylase 1 (LSD1) being developed by Merck for the treatment of myeloproliferative neoplasms (MPNs). LSD1 plays an important role in regulating hematopoietic stem and progenitor cell proliferation, differentiation, and maturation. By inhibiting LSD1, bomedemstat is designed to modulate abnormal hematopoietic cell activity and potentially reduce disease burden and associated symptoms. Currently, the drug is in Phase III stage of its development for the treatment of polycythemia.

DISC-3405: Disc Medicine / Mabwell

DISC-3405 is an investigational monoclonal antibody targeting TMPRSS6 (transmembrane serine protease 6; matriptase-2) to increase endogenous hepcidin production and thereby reduce systemic iron levels. TMPRSS6 regulates iron homeostasis by suppressing hepcidin through inhibition of hemojuvelin (HJV); therefore, its inhibition is expected to enhance hepcidin activity and promote iron restriction. This mechanism is supported by human genetics, as TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA) result in elevated hepcidin levels and impaired iron availability. Formerly known as MWTX-003, DISC-3405 was in-licensed from Mabwell Therapeutics and has completed a Phase I study in healthy volunteers, with Phase II development initiated in polycythemia vera.

AG-236: Agios Pharmaceuticals/Alnylam Pharmaceuticals

AG-236 is an investigational GalNAc-conjugated small interfering RNA (siRNA) targeting TMPRSS6, being developed by Agios Pharmaceuticals for the treatment of polycythemia vera (PV). By silencing TMPRSS6, AG-236 is designed to increase endogenous hepcidin production, thereby reducing iron availability for erythropoiesis and potentially helping control excessive red blood cell production and hematocrit levels in PV. Early Phase I results in healthy volunteers demonstrated sustained hepcidin control and favorable effects on iron-regulation biomarkers without the need for dose titration, supporting the potential for infrequent dosing, potentially up to every six months. According to company’s pipeline the therapy is in Phase I stage of its development for treatment of polycythemia.

Further product details are provided in the report……..

Polycythemia: Therapeutic Assessment

This segment of the report provides insights about the different Polycythemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Polycythemia
• There are approx. 10+ key companies which are developing the therapies for Polycythemia. The companies which have their Polycythemia drug candidates in the most advanced stage, i.e. Phase III include, Merck Sharp & Dohme.
• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Polycythemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polycythemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Polycythemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycythemia drugs.

Polycythemia Report Insights

• Polycythemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polycythemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Polycythemia drugs?
• How many Polycythemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycythemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polycythemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Polycythemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Disc Medicine
• Merck Sharp & Dohme
• Agios
• Prelude Therapeutics
• Silence Therapeutics
• Deciphera
• Ionis
• Ono pharma
• Mabwell

Key Products

• DISC-3405
• Bomedemstat
• AG-236
• Research Program: JAK2V617F
• Divesiran
• Sapablursen